Valuation: Penumbra, Inc.

Market Cap 12.56B 10.94B 10.35B 9.41B 17.57B 1,203B 17.66B 123B 47.69B 611B 47.18B 46.13B 1,957B P/E 2026 *
72.3x
P/E 2027 * 52.1x
Enterprise Value 12.11B 10.55B 9.99B 9.07B 16.95B 1,160B 17.03B 119B 45.99B 590B 45.5B 44.49B 1,887B EV / Sales 2026 *
7.6x
EV / Sales 2027 * 6.57x
Free-Float
97.1%
Yield 2026 *
-
Yield 2027 * -
1 day+0.15%
1 week+0.34%
Current month-1.31%
1 month-2.54%
3 months+0.86%
6 months-5.66%
Current year+2.56%
1 week 317.3
Extreme 317.3
320.31
1 month 317.3
Extreme 317.3
327.77
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Free

Chairperson

3,060 0.0078%
5/19/26 Don

Chief Executive Officer

-77,000 0.1958%
4/2/26 Sell

Director

100 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.34%+24.42%+19.16% 12.56B
-0.67%+1.19%+12.42%+17.43% 6.62B
-1.65%-1.83% - - 6.2B
-0.21%+2.66%+23.70%+12.35% 5.59B
+0.37%+1.60%-19.19%+38.13% 5.06B
+0.73%+2.75%-32.50%-24.76% 3.88B
+3.08%+8.93%+31.76%-13.37% 1.95B
-1.32%-1.31%-17.31%+194.38% 1.75B
-1.95%+2.06%+45.86%-18.51% 1.61B
-1.73%+4.20%-21.06%+34.00% 1.38B
Average -0.25%+1.42%+5.34%+28.76% 4.66B
Weighted average by Cap. -0.21%+0.88%+9.28%+21.11%

Financials

2026 *2027 *
Net sales 1.59B 1.39B 1.31B 1.19B 2.23B 153B 2.24B 15.64B 6.05B 77.53B 5.98B 5.85B 248B 1.8B 1.57B 1.48B 1.35B 2.52B 172B 2.53B 17.67B 6.83B 87.6B 6.76B 6.61B 280B
Net income 176M 154M 145M 132M 247M 16.9B 248M 1.73B 670M 8.59B 663M 648M 27.49B 242M 211M 200M 181M 339M 23.21B 341M 2.38B 920M 11.79B 910M 890M 37.76B
Net Debt -447M -389M -368M -335M -625M -42.81B -629M -4.39B -1.7B -21.76B -1.68B -1.64B -69.65B -729M -635M -601M -546M -1.02B -69.79B -1.02B -7.15B -2.77B -35.47B -2.74B -2.68B -114B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-09-17 US$318.87 +0.15% 416,077
26-09-16 US$318.40 -0.01% 816,975
26-09-15 US$318.43 -0.45% 500,842
26-09-14 US$319.86 +0.67% 269,558
26-09-11 US$317.73 -0.02% 152,618
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
318.87USD
Average target price
361.83USD
Spread / Average Target
+13.47%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!